NightHawk Biosciences Inc (NHWK)

[dia76ca]

What are the implications for the HS-110 + Opdivo lung cancer trial? The poster included these comments.

"Previous clinical trials with the ImPACT platform have shown CD8+ TIL induction after vaccination. In this trial, patients with High TIL at baseline had fewer disease recurrences than patients with Low TIL at baseline – patients with inflamed tumors have better outcomes in many tumor types. However, Low TIL patients treated with vaccine appear to have a similar recurrence rate to High TIL patients. These data support the vaccine mechanism of action of stimulating a CD8+ T-cell response that may be related to clinical outcome."

This indicates that the ImPACT gp96 platform is turning "cold" tumours into "hot" tumours. When combined with checkpoint inhibitors the results could be dramatic.

Trials can be set up targeting patients with "cold" tumours. Third and fourth drugs(eg. OX40 and/or low dose CPA)can be added to increase the efficacy. It is no wonder BMS, Merck and AZN are waiting for further results. I look forward to an HS-110 + Opdivo update!